Overview
Acute pulmonary blastomycosis is a severe fungal infection caused by Blastomyces dermatitidis, typically endemic to certain regions of North America, including parts of the Ohio and Mississippi River valleys, the Great Lakes area, and occasionally seen in unexpected urban settings like greater Toronto [PMID:33619139]. This infection can present with a wide spectrum of clinical manifestations, ranging from mild respiratory symptoms to life-threatening disseminated disease, particularly in immunocompromised individuals or those with underlying comorbidities such as diabetes, renal failure, and chronic obstructive pulmonary disease (COPD). Early recognition and prompt treatment are crucial to prevent progression to acute respiratory distress syndrome (ARDS) and other severe complications. The diagnostic process often poses challenges due to overlapping clinical features with other respiratory infections, necessitating thorough diagnostic workup including appropriate fungal cultures.
Epidemiology
Blastomycosis traditionally has been associated with endemic regions, but recent cases highlight the potential for atypical geographic distribution, even in urban areas without travel history [PMID:33619139]. For instance, a 54-year-old immunocompetent man from greater Toronto presented with acute respiratory distress syndrome (ARDS) due to disseminated blastomycosis, underscoring the importance of considering this diagnosis even in non-endemic urban settings. The disease can affect individuals across various demographics, but those with underlying conditions such as diabetes, hypertension, and renal impairment are at higher risk for severe manifestations [PMID:40084553]. Additionally, occupational exposures, such as construction or landscaping in endemic areas, may increase susceptibility, emphasizing the need for clinicians to inquire about potential environmental exposures in patients presenting with unexplained respiratory symptoms.
Clinical Presentation
The clinical presentation of acute pulmonary blastomycosis can be highly variable, often mimicking other respiratory infections, making early diagnosis challenging. A 55-year-old female with multiple comorbidities including type 2 diabetes, hypertension, end-stage renal disease, hypothyroidism, and COPD developed severe respiratory symptoms including hypotension, fever, shortness of breath, and confusion, ultimately progressing to ARDS [PMID:40084553]. This case illustrates how underlying comorbidities can significantly impact disease severity and outcome. Another patient, a 50-year-old individual, presented with a 2-month history of progressive dyspnea, greenish-yellow sputum production, night sweats, weight loss, and a purulent cutaneous lesion, highlighting the multisystem involvement characteristic of disseminated blastomycosis [PMID:38375745]. Early symptoms often include nonspecific respiratory complaints such as cough, fever, and malaise, which can evolve into more severe manifestations like chest pain, hemoptysis, and systemic symptoms like night sweats and weight loss. The presence of cutaneous lesions or bone involvement further complicates the clinical picture, necessitating a comprehensive evaluation.
Diagnosis
Diagnosing acute pulmonary blastomycosis requires a high index of suspicion and thorough diagnostic evaluation due to its nonspecific clinical presentation and overlap with other respiratory pathogens. Initial empirical antibiotic therapy, while common, can delay the correct diagnosis, as seen in cases where patients were treated for presumed bacterial pneumonia before blastomycosis was identified [PMID:40084553]. Definitive diagnosis typically relies on laboratory confirmation through fungal cultures, including sputum, bronchoalveolar lavage (BAL) fluid, and bone marrow aspirates [PMID:38375745, PMID:33619139]. Imaging findings, such as mass-like opacities or nodular infiltrates on chest radiographs or CT scans, can suggest the diagnosis but are not definitive. Serological tests, including immunodiffusion and enzyme-linked immunosorbent assay (ELISA), can provide supportive evidence but are not always reliable due to variability in antibody responses. Therefore, obtaining appropriate cultures remains the cornerstone of diagnosis, underscoring the importance of including fungal studies in the diagnostic workup of suspected cases.
Differential Diagnosis
Differentiating blastomycosis from other respiratory infections can be complex, often requiring extensive investigations to rule out alternative diagnoses. Autoimmune workups, including antinuclear antibodies (ANA), antineutrophil cytoplasmic antibodies (ANCA), anti-glomerular basement membrane antibodies, rheumatoid factor, and cyclic citrullinated peptide (CCP) antibodies, were negative in one case, emphasizing the need to exclude autoimmune conditions [PMID:38375745]. Initial clinical suspicion might lead to investigations for other infectious etiologies such as mycobacterial infections or malignancies, as evidenced by bronchoscopy findings and imaging that initially suggested these possibilities [PMID:33619139]. Clinicians must consider a broad differential, including viral pneumonias, fungal infections other than blastomycosis (e.g., histoplasmosis, coccidioidomycosis), and opportunistic infections in immunocompromised patients. Comprehensive diagnostic testing, including imaging, serology, and microbiological cultures, is essential to narrow down the differential and confirm the diagnosis accurately.
Management
The management of acute pulmonary blastomycosis involves a multifaceted approach, starting with prompt recognition and transitioning to targeted antifungal therapy. Initial empirical treatment with broad-spectrum antibiotics is common but often delays appropriate antifungal intervention, as seen in cases where patients received antibiotics before definitive diagnosis [PMID:40084553]. Once blastomycosis is confirmed, antifungal agents such as amphotericin B, itraconazole, or voriconazole are typically employed. For severe cases requiring intensive care, such as those progressing to ARDS, prolonged mechanical ventilation and extracorporeal membrane oxygenation (ECMO) may be necessary, as illustrated by a patient requiring ECMO and ongoing mechanical ventilation post-decannulation [PMID:33619139]. Supportive care measures, including fluid management, oxygen therapy, and management of comorbidities, are crucial. In less severe cases, oral itraconazole has shown efficacy, although the specific regimen and duration should be tailored to the patient's clinical status and response. Monitoring for drug interactions and side effects, particularly in patients with multiple comorbidities, is essential.
Complications
Patients with underlying conditions such as diabetes, renal failure, and COPD are at significantly higher risk for blastomycosis to progress to severe complications, including ARDS [PMID:40084553]. Complications can arise rapidly, with diagnostic procedures like bronchoscopy potentially exacerbating respiratory distress, as evidenced by a patient developing worsening hypoxemia and bilateral infiltrates consistent with ARDS post-procedure [PMID:38375745]. Other complications may include disseminated infection affecting multiple organs, such as the skin, bones, and genitourinary tract, leading to a more complex clinical picture and prolonged recovery. Early intervention to prevent these complications is critical, particularly in high-risk patients, to mitigate the risk of fatal outcomes.
Prognosis & Follow-up
The prognosis for acute pulmonary blastomycosis varies widely depending on the severity of the disease at presentation and the timeliness of appropriate treatment. Fatal outcomes, as seen in severe cases progressing to ARDS, underscore the importance of early recognition and intervention [PMID:40084553]. Among canine studies, while not directly translatable to humans, the need for supplemental oxygen was strongly associated with decreased survival rates, suggesting that respiratory support plays a pivotal role in patient outcomes [PMID:28561957]. Post-treatment follow-up should include regular monitoring for recurrence, especially in immunocompromised individuals or those with persistent underlying conditions. Long-term management may involve continued antifungal therapy and close surveillance for potential relapse or complications, ensuring that patients receive comprehensive care to prevent secondary infections and manage comorbidities effectively.
References
1 Zeleke S, Kayali L, Bills E, Tigabe S, White A, Watson V et al.. Fatal Pulmonary Failure-A Rare Case of Blastomycosis Induced Acute Respiratory Distress Syndrome: A Case Report and Literature Review. Journal of investigative medicine high impact case reports 2025. link 2 Vangara A, Gullapalli D, Depa JK, Kolagatla S, Ali M, Ganti SS. Beware of the Acute Respiratory Distress Syndrome in a Pulmonary Blastomycosis!. Journal of investigative medicine high impact case reports 2024. link 3 Agarwal A, Losie JA, Kain D, Kaul R. Blastomycosis with rapid-onset acute respiratory distress syndrome in an urban setting. BMJ case reports 2021. link 4 Walton RAL, Wey A, Hall KE. A retrospective study of anti-inflammatory use in dogs with pulmonary blastomycosis: 139 cases (2002-2012). Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001) 2017. link